Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail Dcri-2400 Pratt Street, Room 0311-BOX 3850, Durham, NC 27710
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Cooper, C, Naggie, S, Saag, M, Yang, JC, Stamm, LM, Dvory-Sobol, H, Han, L, Pang, PS, McHutchison, JG, Dieterich, D, and Sulkowski, M. "Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 63, no. 4 (August 2016): 528-531.

PMID
27225242
Full Text

Braeu, N, Wyles, D, Kottilil, S, Darr, E, Workowski, K, Luetkemeyer, A, Adeyemi, O, Ruane, P, Doehle, B, Huang, KC, Osinusi, A, McNally, J, Natha, M, Guion, M, McLean, T, Brainard, DM, McHutchison, JG, Naggie, S, and Sulkowski, M. "Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase." July 2016.

Scholars@Duke

Patel, K, Kilfoil, G, Wyles, DL, Naggie, S, Lawitz, E, Bradley, S, Lindell, P, and Suhy, D. "258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV)." May 2016.

Full Text

Bhagani, S, Cooper, C, Naggie, S, Saag, M, Yang, J, Stamm, L, Natha, M, Dvory-Sobol, H, McHutchinson, J, Jackson, A, Dieterich, D, and Sulkowski, M. "Retreatment of patients co-infected with HCV and HIV-1 who failed 12 weeks of ledipasvir/sofosbuvir." HIV MEDICINE 17 (April 2016): 38-38.

Scholars@Duke

Alam, I, Brown, K, Donovan, C, Forlenza, J, Lauwers, K, Mah'moud, MA, Manch, RA, Mohanty, SR, Prabhakar, A, Reindollar, R, Sawyerr, G, Slim, J, Tandon, P, Villadiego, S, and Naggie, S. "Su1426 Effectiveness of Simeprevir-Containing Regimens Among Patients With Chronic Hepatitis C Virus in Various US Practice Settings: The SONET Study." April 2016.

Full Text

Ruane, PJ, Shiha, G, Abergel, A, Asselah, T, Kohli, A, Kottilil, S, Naggie, S, Doss, W, Esmat, G, Letterio, CM, Hahambis, TA, Natha, M, Kreter, B, Kersey, K, Brainard, D, and Knox, S. "756 Integrated Analysis of Sof+RBV or LDV/Sof for the Treatment of Genotype 4 Chronic HCV Infection." April 2016.

Full Text

Alam, I, Brown, K, Donovan, C, Forlenza, J, Lauwers, K, Mah’moud, MA, Manch, R, Mohanty, SR, Prabhakar, A, Reindollar, R, Sawyerr, G, Slim, J, Tandon, N, Villadiego, S, and Naggie, S. "Effectiveness of Simeprevir-Containing Regimens among Patients with Chronic Hepatitis C Virus in Various Us Practice Settings: The Sonet Study." 2016.

Full Text

Wyles, D, Brau, N, Kottilil, S, Daar, E, Workowski, K, Luetkemeyer, A, Adeyemi, O, Ruane, P, Doehle, B, Huang, K, Osinusi, A, McNally, J, Brainard, D, McHutchison, J, Naggie, S, and Sulkowski, M. "Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study." 2016.

Full Text

Esmat, GE, Shiha, G, Abergel, A, Asselah, T, Kohli, A, Kottilil, S, Ruane, PJ, Naggie, S, Doss, WH, Hahambis, TA, Letterio, C, Natha, M, Kreter, B, Kersey, K, Brainard, D, and Knox, SJ. "INTEGRATED ANALYSIS OF SOF plus RBV OR LDV/SOF FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HCV INFECTION." 2016.

Scholars@Duke

Suhy, D, Patel, K, Kilfoil, G, Wyles, DL, Naggie, S, Lawitz, E, Bradley, S, and Lindell, P. "Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV)." HEPATOLOGY 62, no. 6 (December 2015): 1386A-1386A.

Scholars@Duke

Pages